Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash ...

Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer ...

Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain ...

The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth ...

Bio-Rad Laboratories has delivered a sharp mix of outcomes for long term holders, with the stock down about 52.9% over 5 years even as shorter term returns have turned positive. This puts the ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that through its Exact ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ...

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...

The stock price of Bio-Rad Laboratories (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 10% rise over the last twenty-one trading days, while it is up 30% ...